>_ QFI Terminal
TerminalStocks › QGEN

Qiagen N.V. (QGEN) Stock

Healthcare · Medical - Diagnostics & Research · US
$36.95 +1.01%
Last updated Jun 18, 2026 23:57 UTC

QGEN Key Statistics

Market Cap$7.62B
P/E (TTM)19.55
P/S (TTM)3.63
P/B (TTM)2.30
Revenue (TTM)$2.10B
EPS (TTM)$1.89
Dividend Yield0.53%
ROE (TTM)11.28%
Net Margin19.16%
Gross Margin61.58%
52W High$57.82
52W Low$32.53
Analyst ViewHold
Price Target$45.17
Employees5,700
Volume1,442,935

About Qiagen N.V.

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

CEO: Thierry L. Bernard. Company website

See QGEN live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open QGEN in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.